Day Zero Diagnostics
Latest round
- Series A
Last raised
- Feb 2022
Total raised
- $33M
Investors
- 6
About Day Zero Diagnostics
Based in the US, Day Zero Diagnostics, Inc.Founded in 2016 in Boston, US, Day Zero Diagnostics, Inc. focuses on innovating diagnostics for infectious diseases. The company was co-founded by Douglas Kwon, Jong Lee, Melis Anahtar, and Miriam Huntley.Day Zero Diagnostics Inc. (DZD) specializes in rapid diagnostics for infectious diseases, utilizing whole genome sequencing to deliver same-day identification (ID) and antimicrobial susceptibility testing (AST) directly from blood samples, circumventing traditional culture-based methods. Their flagship offering, the rapid antimicrobial susceptibility testing, empowers healthcare professionals to make informed treatment decisions by providing comprehensive organism identification and resistance profiling within hours. This innovation addresses critical healthcare challenges, particularly in the treatment of life-threatening infections like sepsis, where timely intervention is essential. DZD's services are primarily targeted at hospitals and healthcare facilities where the threat of antibiotic resistance is significant, with applications spanning both domestic and international markets including the United States and select regions in Europe.Day Zero Diagnostics generates revenue through direct partnerships with healthcare institutions and healthcare providers, leveraging their advanced diagnostic solutions as part of clinical workflows. These collaborations typically involve service agreements where hospitals and laboratories subscribe to DZD’s rapid testing technology, resulting in a seamless integration into their infectious disease management protocols. Transactions are structured as B2B agreements, focusing on service usage fees that are contingent on the volume of tests conducted, thereby aligning DZD’s offerings with the needs of its client base. The company’s revenue model is supported by their proprietary products, including the rapid antimicrobial susceptibility testing and the epiXact® service, which are critical in addressing the increasing urgency of antibiotic resistance in clinical settings.In September 2023, Day Zero Diagnostics, Inc. Furthermore, DZD plans to expand into additional international markets, specifically targeting regions in Europe and Asia, by the end of 2024.
Who invested in Day Zero Diagnostics
6 investors across 3 rounds
See all investors in Day Zero Diagnostics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Day Zero Diagnostics
Who invested in Day Zero Diagnostics?
Day Zero Diagnostics has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Day Zero Diagnostics raised?
Day Zero Diagnostics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Day Zero Diagnostics last raise money?
Day Zero Diagnostics's most recent round on record is a Series A, in Feb 2022.
What does Day Zero Diagnostics do?
Based in the US, Day Zero Diagnostics, Inc.
Where is Day Zero Diagnostics headquartered?
Day Zero Diagnostics is headquartered in Boston, US.
Which VCs invest in companies like Day Zero Diagnostics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back medical devices & equipment companies at Day Zero Diagnostics's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series A
Raising like Day Zero Diagnostics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.